Stock Analysis of BioLineRx Ltd (BLRX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BLRX
Close 0.640
Change -0.0019 / 0.296 %
Volume 307343
Vol Change -314683.00 / 50.59 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of BioLineRx Ltd
PE (TTM)

-8.03

Very Poor
Price / Book

17.71

Very Poor
Price / Sales

101.37

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

51161.15 K

Enterprise Value

57207.15 K

ROA (TTM)

-94.49

Very Poor
ROE (TTM)

-220.63

Very Poor
Net Margin (TTM)

-1262.79

Very Poor
Revenue

%

4800.00 K
Net Profit

177.98 %

-52461.00 K
Debt to Equity

0.779

Good
Altman Z Score

-10.09

Very Poor
Quick Ratio

1.47

Indecisive
Cash Ratio

1.39

Indecisive


Highs/Lows of BioLineRx Ltd
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.652 1.84 % 1.54 % 0.680.617-May-2415-May-24
Two Week0.68 5.88 % 3.42 % 0.720.607-May-2415-May-24
One Month0.6214 2.99 % 5.60 % 0.720.552807-May-2426-Apr-24
Three Month1.25 48.80 % 5.95 % 1.440.552801-Mar-2426-Apr-24
Six Months1.69 62.13 % 17.48 % 1.890.552808-Dec-2326-Apr-24
One year1.5 57.33 % 27.52 % 2.530.552805-Sep-2326-Apr-24
Two year1.32 51.52 % 29.70 % 2.530.5505-Sep-2310-Mar-23
Five year5.451 88.26 % 85.46 % 2.530.5505-Sep-2310-Mar-23
Ten year30.0 97.87 % 182.41 % 49.20.5505-Mar-1510-Mar-23


Technical View of BioLineRx Ltd
RSI

41.89

Neutral
MACD

-0.0455

Bullish
ADX

33.40

Mild Bearish
Super Trend

0.778

Mild Bearish
Williams %R

-66.67

Neutral
CCI

-15.34

Neutral


EMA 5

0.640

Neutral
EMA 15

0.656

Mild Bearish
EMA 50

0.811

Strong Bearish
EMA 100

1.00

Mild Bearish
SMA 100

1.07

Mild Bearish
SMA 200

1.34

Strong Bearish
SMA 5 / 20

0.633 / 0.650

Bearish
SMA 15 / 50

0.659 / 0.832

Mild Bearish
SMA 50 / 200

0.832 / 1.34

Strong Bearish




Charts of BioLineRx Ltd


Returns of BioLineRx Ltd with Peers
Period / StockBLRXCTSOALGSCDTX
1 Week-1.84%6.38%-5.72%-7.81%
1 Mth2.99%22.48%-12.52%-22.39%
3 Mth-48.80%-4.20%5.92%-21.60%
6mth-62.13%-15.12%0.364%-28.14%
1 Year-57.33%-72.74%-42.14%-58.48%
2 Year-51.52%-54.79%-40.13%16.05%
5 Years-88.26%-86.00%--72.25%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of BioLineRx Ltd with Peers
Ratio / StockBLRXCTSOALGSCDTX
PE-8.03-1.68-270.26-1.22
P/B17.712.03372.705.70
ROA-94.49-53.41-83.61-45.72
ROE-220.63-121.04-137.90-468.73
Debt To Equity0.7790.2330.0352-0.158
Revenue4800.00 K
% 		31378.49 K
9.54 % 		15529.00 K
11.66 % 		56541.00 K
12.05 %
Net Income-52461.00 K
177.98 % 		-23438.61 K
28.57 % 		-87679.00 K
8.71 % 		-30697.00 K
3.01 %


Technicals of BioLineRx Ltd with Peers
Technical / StockBLRXCTSOALGSCDTX-
ADX33.4014.8220.4114.31
CMF0.082-0.058-0.156-0.124
MFI65.4556.9447.6145.78
RSI41.8959.2337.1638.03
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : BioLineRx Ltd

Address : Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
Tel : 972 8 642 9100
URL : https://www.biolinerx.com
Code : BLRX, ISIN : US09071M2052, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 25_Jul_2011
Employee Count : 79

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.


Note : All Data Generated at the End of Trading Hours (EOD Data)